Theriva Biologics, Inc. Income Tax Expense
Theriva Biologics, Inc. (TOVX) reported Income Tax Expense of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2025-03-06
- Theriva Biologics, Inc. income tax expense (benefit) for the quarter ending 2023-12-31 was -$424.00K.
- Theriva Biologics, Inc. income tax expense (benefit) for the quarter ending 2023-09-30 was -$527.00K.
- Theriva Biologics, Inc. income tax expense (benefit) for the quarter ending 2023-06-30 was -$359.00K.
- Theriva Biologics, Inc. income tax expense (benefit) for the quarter ending 2023-03-31 was -$330.00K.
- Theriva Biologics, Inc. income tax expense (benefit) for fiscal 2024 was $0.00.
- Theriva Biologics, Inc. income tax expense (benefit) for fiscal 2023 was -$1.64M.
- Theriva Biologics, Inc. income tax expense (benefit) for fiscal 2022 was -$1.43M.
- Theriva Biologics, Inc. income tax expense (benefit) for fiscal 2021 was $0.00.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-06 | |||
| 2023-12-31 | -$424.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$951.00K derived: sum of 2 quarters · filed 2025-03-06 | -$1.31M derived: sum of 3 quarters · filed 2025-03-06 | -$1.64M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$527.00K 10-Q · filed 2024-11-12 | -$886.00K derived: sum of 2 quarters · filed 2024-11-12 | -$1.22M 10-Q · filed 2024-11-12 | -$1.77M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$359.00K 10-Q · filed 2024-08-13 | -$689.00K 10-Q · filed 2024-08-13 | -$1.25M derived: sum of 3 quarters · filed 2024-08-13 | -$1.58M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$330.00K 10-Q · filed 2024-05-07 | -$888.00K derived: sum of 2 quarters · filed 2024-05-07 | -$1.22M derived: sum of 3 quarters · filed 2024-05-07 | -$1.75M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$558.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$893.00K derived: sum of 2 quarters · filed 2024-03-25 | -$1.43M derived: sum of 3 quarters · filed 2024-03-25 | -$1.43M 10-K · filed 2024-03-25 |
| 2022-09-30 | -$335.00K 10-Q · filed 2023-11-13 | -$867.00K derived: sum of 2 quarters · filed 2023-11-13 | -$867.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$532.00K 10-Q · filed 2023-08-08 | -$532.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-30 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-16 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-04 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-02-20 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-02-27 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-02-22 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-03-02 | |||
| 2014-12-31 | $0.00 10-K · filed 2016-03-10 | |||
| 2013-12-31 | $0.00 10-K · filed 2015-03-16 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-16 | |||
| 2011-12-31 | $0.00 10-K · filed 2013-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |